Astria's ALPHA-STAR Trial Breakthrough
Astria reports a 90-95% attack reduction in HAE trial, with STAR-0215 progressing to Phase 3 by 2025.
Astria Therapeutics has announced positive results from its ALPHA-STAR Phase 1b/2 trial evaluating navenibart (STAR-0215) for hereditary angioedema (HAE). The trial showed a 90-95% reduction in monthly attack rates over six months, with no serious adverse events and favorable tolerability. Results support three- and six-month dosing schedules.
Astria plans to initiate Phase 3 development in Q1 2025, with topline results expected by late 2026. All patients have joined an ongoing long-term trial to evaluate safety and efficacy further, with interim data expected mid-2025.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion